eISSN (Online): 2598-0580



Bioscientia Medicina: Journal of Biomedicine & Translational Research

Journal Homepage: www.bioscmed.com

Giant Gastric GIST Manifesting as Profound Iron Deficiency Anemia: A Case Report of a Diagnostic Pitfall

Suri Hanifa Efendi[1*], Saptino Miro[2]

[1]Department of Internal Medicine, Faculty of Medicine, Universitas Andalas/Dr. M. Djamil General Hospital, Padang, Indonesia

[2]Division of Gastroenterohepatology, Department of Internal Medicine, Faculty of Medicine, Universitas Andalas/Dr. M. Djamil General Hospital, Padang, Indonesia

ARTICLE INFO

Keywords:
Case report
Diagnostic error
Gastric polyp
Gastrointestinal stromal tumor
Iron deficiency anemia

***Corresponding author:**
Suri Hanifa Efendi

E-mail address:
surihanifaefendi@gmail.com

All authors have reviewed and approved the final version of the manuscript.

https://doi.org/10.37275/bsm.v9i8.1366

A B S T R A C T

Background: Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal neoplasms of the gastrointestinal tract, yet they remain rare, particularly in patients under 40. Their clinical presentation is highly variable, often posing a diagnostic challenge. Severe anemia as the initial manifestation is common, but diagnostic confusion with benign lesions on initial biopsy is a significant clinical pitfall. **Case presentation:** A 39-year-old male presented with a three-month history of epigastric pain, early satiety, significant weight loss, and profound fatigue. His initial hemoglobin was a life-threatening 3.8 g/dL, consistent with profound iron deficiency anemia. Esophagogastroduodenoscopy (EGD) revealed a large, partially obstructing mass in the gastric corpus. However, initial endoscopic biopsies were paradoxically reported as a benign hyperplastic polyp. In contrast, contrast-enhanced computed tomography (CT) of the abdomen characterized a massive, 9.9 x 7.3 x 13.5 cm heterogeneously enhancing mass suggestive of malignancy. Given the stark discrepancy between imaging and histology, a decision was made for surgical intervention. The patient underwent a total gastrectomy. Final histopathological analysis of the resected specimen, supported by immunohistochemistry, confirmed a high-risk gastrointestinal stromal tumor with a high mitotic rate. **Conclusion:** This case underscores the critical importance of maintaining a high index of suspicion for GIST in patients with unexplained iron deficiency anemia, even in younger age groups. It highlights the potential for sampling error with endoscopic biopsies of large submucosal tumors, which can lead to dangerously misleading diagnoses. Clinicians must integrate clinical, radiological, and endoscopic findings to guide management, especially when histopathological results are incongruent with the overall clinical picture.

1. Introduction

Gastrointestinal stromal tumors (GISTs) represent the most prevalent mesenchymal neoplasms originating within the gastrointestinal (GI) tract. Despite this distinction, they are fundamentally rare tumors, constituting only 1-2% of all primary GI neoplasms.[1,2] The incidence of GISTs is estimated to be between 10 to 15 cases per million people per year in Western countries, with a slight variation in Asian populations.[3] These tumors are thought to arise from the interstitial cells of Cajal (ICCs) or their precursors, the pacemaker cells responsible for coordinating gut motility.[4] This cellular origin is pivotal to their biology and is defined by the expression of the KIT protein (CD117), a receptor tyrosine kinase that serves as the hallmark immunohistochemical marker for diagnosis.[5] The vast majority of GISTs (approximately 80-85%) are driven by gain-of-function mutations in the KIT proto-oncogene. A smaller subset, about 5-10%, harbors activating mutations in a related receptor tyrosine kinase gene, platelet-derived growth factor receptor alpha (PDGFRA).[6,7] These mutations lead to constitutive, ligand-independent activation of the kinase, resulting in uncontrolled cellular proliferation and survival, which is the cornerstone of GIST pathogenesis. This molecular understanding has not only refined diagnosis but has also revolutionized treatment, leading to the development of targeted therapies like imatinib mesylate, which has dramatically improved outcomes for patients with advanced or metastatic disease.[8]

The clinical presentation of GISTs is notoriously heterogeneous and largely dependent on tumor size and location. They can occur anywhere along the GI tract, but the stomach is the most common site (60-70%), followed by the small intestine (20-30%), with rare occurrences in the colon, rectum, and esophagus.[9] Smaller tumors (<2 cm) are often asymptomatic and discovered incidentally during imaging or endoscopic procedures performed for other indications. Larger tumors, however, are more likely to be symptomatic. Patients may present with vague, non-specific symptoms such as abdominal pain, nausea, vomiting, or early satiety.[1,10] A palpable abdominal mass is a less frequent finding, typically associated with very large tumors. One of the most significant clinical manifestations of GISTs is gastrointestinal bleeding, which can be acute and dramatic (hematemesis or melena) or, more commonly, chronic and occult.[11] This chronic, low-grade blood loss is a frequent consequence of mucosal erosion or ulceration overlying the surface of the tumor, which becomes friable and prone to bleeding as it grows. This insidious blood loss invariably leads to the development of iron deficiency anemia (IDA), which may be the sole presenting feature of the disease.[12] The resulting symptoms of anemia—fatigue, pallor, dyspnea on exertion, and weakness—may dominate the clinical picture, often prompting extensive investigation before the underlying tumor is discovered. The prevalence of IDA in patients with GI cancers is substantial, ranging from 30% to 60%, and is particularly pronounced in gastric malignancies where mechanical factors and malabsorption can be exacerbated.[13]

The diagnosis of GIST is a multi-modal process. Contrast-enhanced computed tomography (CT) is the imaging modality of choice for identifying the primary tumor, assessing its size and extent, and detecting any potential metastatic disease, most commonly to the liver or peritoneum.[14] Endoscopy is crucial for direct visualization and biopsy. However, because GISTs are submucosal tumors, originating from the muscularis propria layer, the overlying mucosa may appear normal or only subtly raised. Standard endoscopic forceps biopsies, which sample only the superficial mucosal layers, may fail to retrieve diagnostic tissue, leading to a non-diagnostic or, more perilously, a misrepresentative result.[15] This sampling error represents a major diagnostic pitfall.

GISTs typically affect older adults, with a median age at diagnosis between 60 and 65 years, and are exceptionally rare in individuals under the age of 40.[16] When they do occur in younger patients, they may be associated with specific genetic syndromes, such as Carney triad or Neurofibromatosis type 1 (NF1), although most are sporadic.[17] This report details the case of a 39-year-old male who presented with life-threatening iron deficiency anemia caused by a giant gastric GIST. The novelty and aim of this study are to highlight a critical diagnostic pitfall where initial endoscopic biopsies misleadingly suggested a benign hyperplastic polyp, creating significant clinical confusion that was only resolved by prioritizing the contradictory, but ultimately correct, radiological evidence. This case serves as a powerful reminder of the limitations of superficial biopsies for submucosal lesions and champions an integrated diagnostic approach in the workup of severe, unexplained anemia.

2. Case Presentation

The patient at the center of this remarkable case is a 39-year-old male, a man in what should have been the prime of his life, with no significant prior medical history save for the social habit of smoking. His life, however, took a dramatic and insidious turn over a period of three months, as his body began to send a cascade of increasingly alarming signals that something was gravely wrong. This case chronicles his journey from a state of robust health to a perilous clinical crisis, a path defined by debilitating symptoms, profound physiological derangement, and a diagnostic conundrum that would challenge the very principles of clinical reasoning. The initial manifestation was subtle, a creeping fatigue that was easily dismissed as the product of a demanding job or insufficient rest. Yet, this was no ordinary tiredness. Over weeks, it evolved into a profound state of weakness and lethargy, a leaden exhaustion that clung to him from the moment he awoke. His stamina evaporated, transforming simple daily tasks into monumental efforts and rendering him a shadow of his former self. Concurrently, a new and more visceral symptom emerged: a persistent pain localized to his epigastrium. It was not a dull ache but a sharp, stabbing sensation that would ambush him with particular ferocity after meals, turning the basic pleasure of eating into an ordeal to be dreaded. This post-prandial assault was soon joined by a distressing sense of early satiety; a few bites of food were enough to make him feel uncomfortably full, as if his stomach had physically shrunk. Nausea became a constant companion, often culminating in non-bloody vomiting that offered no relief. This constellation of symptoms—pain, early satiety, and nausea—precipitated a precipitous decline in his nutritional status. His appetite waned, and with it, his body mass. Over the three-month period, he lost a staggering 10 kilograms, a physical testament to the silent catabolic process unfolding within him. Perhaps the most ominous sign during this period was the intermittent appearance of melena. The passage of black, tarry stools, a definitive sign of upper gastrointestinal bleeding, was a recurring but inconsistent event, a sinister clue that was difficult to ignore. The cumulative effect of these symptoms led him to seek medical attention, culminating in his admission for an exhaustive investigation. Upon formal clinical assessment, the physical examination immediately corroborated the severity of his condition. His skin and mucous membranes were strikingly pale, with a marked conjunctival pallor that spoke volumes of a profound underlying anemia. His cardiovascular system was clearly under strain; a persistent tachycardia, with a heart rate of 100 beats per minute, represented his heart's desperate, compensatory effort to circulate what little oxygen-carrying capacity his blood retained. Palpation of his abdomen pinpointed the epicenter of his distress, revealing a distinct and reproducible tenderness in the epigastric region, though thankfully without any signs of peritonitis, such as rigidity or rebound tenderness. The true magnitude of the physiological crisis was laid bare by the initial laboratory investigations. The results were not merely abnormal; they were life-threatening. His hemoglobin level was a catastrophic 3.8 g/dL, a value less than one-third of the lower limit of normal for an adult male and a level teetering on the edge of cardiovascular collapse. The anemia was profoundly microcytic and hypochromic, with a mean corpuscular volume (MCV) of 67 fL, indicating that the red blood cells being produced were small and starved of hemoglobin. The iron profile provided the definitive explanation for this hematological disaster. The patient's iron stores were, for all practical purposes, nonexistent. A serum ferritin level of 1.84 ng/mL is indicative of a complete and utter depletion of the body's iron reserves. This finding, combined with a low serum iron and a low transferrin saturation of 5.16%, confirmed a diagnosis of severe, advanced iron deficiency anemia, unequivocally pointing to a chronic and significant blood loss as the underlying etiology. With the source of bleeding localized to the upper gastrointestinal tract by the patient's symptoms and the presence of melena, an urgent esophagogastroduodenoscopy (EGD) was performed. The endoscopic journey into the stomach revealed a breathtakingly abnormal landscape. There, originating from the gastric corpus, was a massive, lobulated, and grotesque tumor. It was so large that it filled and nearly obliterated the gastric lumen, making further passage of the endoscope a physical impossibility. The surface of the mass was irregular and showed areas of ulceration, providing a clear visual source for the patient's chronic hemorrhage. To delineate the full extent of the disease and to search for any potential spread, a contrast-enhanced computed tomography (CT) scan of the abdomen was performed. The CT images provided a stark, three-dimensional confirmation of the endoscopic findings and painted an even more dramatic picture. The scan characterized a giant, heterogeneously enhancing mass measuring an astonishing 9.9 x 7.3 x 13.5 cm. The tumor appeared to arise from the lesser curvature of the stomach, growing both inward (intraluminally) and outward (exophytically), displacing adjacent structures like the pancreas. Critically, the scan showed no evidence of direct invasion into neighboring organs and, most importantly, no signs of the distant metastases that would have signaled an incurable stage of the disease (Figure 1).

Clinical Findings: A Case Summary

Giant Gastric GIST & Profound Anemia

CATEGORY	FINDING
Demographics	39-year-old male
Presenting Symptoms	3-month history of: Profound fatigue & weakness, epigastric pain (stabbing, post-prandial), early satiety, nausea, 10 kg weight loss, intermittent melena.
Physical Examination	Marked conjunctival pallor, tachycardia (100 bpm), distinct epigastric tenderness without peritoneal signs.
Laboratory & Iron Profile	**Hemoglobin: 3.8 g/dL**, Hematocrit: 13%, MCV: 67 fL. **Serum Ferritin: 1.84 ng/mL**, Serum Iron: 17 µg/dL, Saturation: 5.16%.
Imaging & Endoscopy	**EGD:** Large, lobulated, partially ulcerated mass causing near-complete obstruction. **CT Scan: Massive 9.9 × 7.3 × 13.5 cm** heterogeneously enhancing mass. No distant metastases.
Diagnostic Challenges	**Initial Biopsy Result: Hyperplastic Polyp**. Starkly discordant with all other clinical and radiological findings. ***H. pylori* Serology:** IgM Positive, suggesting a concurrent acute infection.

Figure 1. Clinical finding: a case summary.

The timeline of his care, as outlined in the provided Figure 2, serves as a narrative blueprint, detailing a path from a life-threatening emergency to a structured plan for long-term survival. This account will deconstruct that timeline, transforming the data points into a rich, scientific narrative that illuminates the clinical reasoning and significance behind each critical step. The patient’s journey began not with a subtle decline but with a precipitous fall into a state of profound physiological crisis. His admission to the hospital on Day 1 marked the culmination of a three-month siege on his body, but it was the objective data from this initial encounter that revealed the true, terrifying extent of his condition. The immediate priority was not diagnosis but resuscitation. The finding of an initial hemoglobin (Hb) level of 3.8 g/dL is a number that commands the absolute and undivided attention of any clinician. It represents a state of anemia so severe that it threatens the very oxygen supply to the body’s most vital organs—the heart, the brain, and the kidneys. At this level, the patient is on the precipice of multi-organ failure and cardiovascular collapse. The immediate intervention, stabilization with intravenous (IV) fluids, was the critical first step. While not a replacement for blood, IV fluids are essential to support the circulatory system, maintain blood pressure, and ensure there is adequate intravascular volume for the beleaguered heart to pump. This act of hemodynamic support is the foundational element upon which all subsequent life-saving measures are built. It buys precious time, creating a window of stability in which the true deficit—the catastrophic loss of red blood cells—can be addressed. The notation "Initial Hb 3.8 g/dL" is not just a data point; it is the opening scene of a medical drama, setting the stage for an urgent and aggressive response. The period spanning from Day 1 to Day 3 was defined by a focused and aggressive rescue operation. With the patient hemodynamically supported, the core problem of the anemia was tackled head-on through the transfusion of six units of Packed Red Blood Cells (PRBCs). This intervention is the cornerstone of treating severe, symptomatic anemia. Each unit of PRBCs delivers a concentrated volume of oxygen-carrying red blood cells, directly replenishing the patient's depleted reserves. The administration of six units over a 48-to-72-hour period represents a massive and rapid restoration of this vital capacity, a transfusion volume reserved for cases of extreme hemorrhage or profound, life-threatening anemia. Concurrently, the initiation of oral iron therapy marked the beginning of a longer-term strategy. While transfusion addresses the immediate crisis, it does not correct the underlying iron deficiency that caused the anemia. The body's iron stores were completely exhausted, and rebuilding them is a slow process that requires sustained supplementation. Starting iron therapy early, even as transfusions are ongoing, is crucial for supporting the bone marrow's own efforts to produce new, healthy red blood cells once the immediate crisis has passed. The outcome of these interventions was both immediate and profoundly positive. The patient's hemoglobin level rose dramatically to 8.2 g/dL. This doubling of his hemoglobin concentration, while still well below the normal range, represented a monumental leap away from the immediate threat of death. It lifted him from a state of critical instability to one of relative safety. This physiological improvement was mirrored in his clinical condition; the note that the "Patient symptomatically improved" signifies that the crushing fatigue, the breathlessness, and the cardiac strain began to recede. This successful stabilization was not just a therapeutic victory; it was a strategic one. It created a stable physiological platform from which the essential, and potentially invasive, diagnostic workup could be safely launched.

With the patient out of immediate danger, the focus pivoted from rescue to investigation. The clinical team now had to answer the critical question: what was the source of this catastrophic, chronic blood loss? The diagnostic pursuit began on Day 4 with an Esophagogastroduodenoscopy (EGD). This procedure, which involves passing a flexible camera into the esophagus, stomach, and duodenum, is the gold standard for visualizing the upper gastrointestinal tract. The finding was immediate and unambiguous: a "Large gastric mass visualized." This was the smoking gun. The EGD provided direct, irrefutable evidence of a significant pathological entity within the stomach, almost certainly the source of the bleeding. The endoscopist would have noted its size, its lobulated surface, and areas of ulceration, all features pointing towards a large neoplasm. Biopsies were taken, small fragments of tissue plucked from the tumor's surface, destined for the pathology lab to provide a definitive name to this menacing entity. On Day 5, the investigation deepened with a contrast-enhanced CT scan of the abdomen. While the EGD provided a direct look at the inner lining of the stomach, the CT scan offered a comprehensive, three-dimensional map of the abdomen, allowing the clinicians to see through the stomach wall and assess the full extent of the tumor and its relationship with surrounding organs. The CT scan confirmed the EGD findings in spectacular fashion, characterizing the lesion as a "Giant gastric mass confirmed (9.9 x 13.5 cm), suspicious for GIST." The term "giant" is not used lightly in radiology reports; a tumor of this magnitude is a formidable presence. The description of it being "suspicious for GIST" (Gastrointestinal Stromal Tumor) was based on its typical appearance on CT: a large, well-defined mass that enhances with contrast, often with areas of internal necrosis or hemorrhage, and tending to grow outwards (exophytically) as well as inwards. Crucially, the CT scan delivered a piece of profoundly good news: "No metastases." The disease, however large and aggressive it appeared locally, had not yet spread to distant sites like the liver or peritoneum. This single finding dramatically altered the patient’s prognosis, transforming the situation from a likely incurable, systemic disease to a potentially curable, localized one.

Just as the clinical picture seemed to be coalescing into a clear diagnosis, the journey took a sharp, bewildering turn. On Day 8, the histopathology report from the EGD biopsies arrived, and its contents were stunningly discordant with every other piece of evidence. The report read: "Hyperplastic Polyp." This finding was not just unexpected; it was, in the context of the clinical scenario, almost impossible. A hyperplastic polyp is a benign, often tiny, non-cancerous growth of the stomach lining, typically arising in response to inflammation. It is a common and generally harmless finding. To receive this diagnosis in a patient with a life-threatening anemia and a 14-centimeter tumor created a moment of profound clinical dissonance. This was the "Diagnostic Pitfall," a critical juncture where an uncritical acceptance of a single test result could have led to a catastrophic delay in treatment. A hyperplastic polyp simply could not account for the patient's condition. The clinical team was faced with a stark choice: to trust the "hard evidence" of a tissue diagnosis or to trust the overwhelming weight of the clinical presentation and the unambiguous radiological findings. This moment underscores the art of medicine, where clinical judgment and the ability to recognize when a piece of data does not fit the larger puzzle are paramount. The team correctly inferred that the biopsies, taken from the surface of the massive submucosal tumor, had only skimmed the reactive, inflamed mucosa overlying the true lesion, thus failing to sample the actual neoplastic cells.

The diagnostic conundrum of Day 8 necessitated the convening of a Multidisciplinary Team (MDT) Meeting on Day 9. This meeting, bringing together gastroenterologists, radiologists, surgeons, and pathologists, is the hallmark of modern cancer care. It provides a forum for synthesizing all available data and forging a consensus on the best path forward. The team collectively reviewed the clinical history, the dramatic laboratory findings, the endoscopic images, and the CT scans. When weighed against this mountain of evidence, the single, discordant biopsy report was correctly identified as a non-representative sampling error. The decision was made to proceed directly to surgery. This was a bold but necessary choice, predicated on the high degree of confidence that a significant, bleeding malignancy was present, regardless of the benign biopsy report. To ensure the patient was in the best possible condition to withstand a major operation, two additional units of PRBCs were transfused. This final "top-up" brought his hemoglobin to a safe and stable pre-operative level of 10.1 g/dL. This meticulous optimization reflects a commitment to minimizing surgical risk and ensuring the patient had the physiological reserve to tolerate the significant stress of the impending procedure. On Day 15, the patient was taken to the operating room for the definitive therapeutic intervention: a Total Gastrectomy. This procedure involves the complete removal of the stomach. While a partial gastrectomy might be considered for smaller, more favorably located tumors, the giant size of this patient's mass and its location likely made it impossible to achieve a safe, cancer-free margin while preserving any part of the stomach. The primary goal of cancer surgery is to achieve an "R0 resection"—the complete removal of the tumor with no cancer cells left behind at the microscopic level. The report that an "R0 resection achieved" is the most important determinant of a successful surgical outcome and the patient’s best chance for a cure. The entire specimen, now liberated from the patient, was sent to the pathology department for the final, definitive analysis that would resolve the diagnostic mystery once and for all. The final act of the diagnostic drama unfolded on Day 21, with the return of the final histopathology and immunohistochemistry report from the resected specimen. The truth was finally unveiled: "Definitive Diagnosis: High-Risk GIST." The microscopic examination of the entire tumor revealed the characteristic spindle-shaped cells of a GIST, and immunohistochemical stains would have confirmed strong positivity for the proteins KIT (CD117) and DOG1, the molecular fingerprints of this tumor type. The designation "High-Risk" was based on the tumor's large size and a high mitotic rate (the speed at which the cancer cells were dividing), two key factors that predict a significant likelihood of recurrence after surgery alone. This definitive diagnosis not only provided an answer but also, critically, provided a roadmap for the next phase of treatment. The patient's immediate post-operative course was smooth and "uneventful," a testament to the skilled surgical intervention and the meticulous pre-operative optimization. He was stable, able to tolerate a new diet without a stomach, and was discharged from the hospital on Post-Op Day 7, a standard recovery timeline for such a major procedure. However, the journey was far from over. The "High-Risk" nature of his GIST necessitated further treatment to reduce the chance of the cancer returning. The 1-Month Follow-up with an oncologist was a pivotal appointment where the plan for "adjuvant therapy initiated" was formalized. The final entry in the timeline, "Ongoing," encapsulates the modern approach to high-risk cancer care. The patient was started on Adjuvant therapy with Imatinib Mesylate (400 mg/day) for a duration of three years. Imatinib is a targeted therapy, a "smart drug" that specifically blocks the KIT protein that drives the growth of GIST cells. For patients with high-risk GISTs, three years of adjuvant imatinib has been proven in clinical trials to dramatically reduce the risk of recurrence and improve long-term survival. Alongside this therapy, he would undergo regular surveillance imaging (CT scans) to monitor for any signs of recurrence. This ongoing phase of care represents a long-term partnership between the patient and his oncology team, a vigilant and proactive strategy to secure the cure that was so skillfully achieved in the operating room.

Timeline of Key Diagnostic & Therapeutic Interventions

A Step-by-Step Overview of Patient Care

TIME POINT	EVENT / INTERVENTION	KEY FINDING / OUTCOME
Day 1	Admission to hospital.	Stabilized with IV fluids. Initial Hb 3.8 g/dL.
Day 1-3	Transfusion of 6 units Packed Red Blood Cells (PRBCs). Oral iron therapy initiated.	Hemoglobin increased to 8.2 g/dL. Patient symptomatically improved.
Day 4	Esophagogastroduodenoscopy (EGD) with biopsy.	Large gastric mass visualized.
Day 5	Contrast-enhanced CT scan of the abdomen.	Giant gastric mass confirmed (9.9 × 13.5 cm), suspicious for GIST. No metastases.
Day 8	Histopathology from EGD biopsy reported.	⚠ Diagnostic Pitfall: Report of "Hyperplastic Polyp."
Day 9	Multidisciplinary Team (MDT) Meeting. Transfusion of 2 additional units of PRBCs.	Decision to proceed to surgery. Pre-operative Hb target >10 g/dL achieved (10.1 g/dL).
Day 15	Surgical Intervention: Total Gastrectomy.	R0 resection achieved. Specimen sent for definitive pathology.
Day 21	Final Histopathology and Immunohistochemistry reported.	✓ Definitive Diagnosis: High-Risk GIST.
Post-Op Day 7	Discharge from hospital.	Patient stable, tolerating diet. Postoperative course was uneventful.
1-Month Follow-up	Oncology consultation.	Plan for adjuvant therapy initiated.
Ongoing	Adjuvant therapy with Imatinib Mesylate (400 mg/day) for 3 years. Regular surveillance imaging.	Patient remains under close follow-up for monitoring of recurrence.

Figure 2. Timeline of key diagnostic and therapeutic interventions.

3. Discussion

To truly appreciate the clinical challenges presented by this case, one must first understand the fundamental biology of the tumor itself. Gastrointestinal stromal tumors are not epithelial cancers like the far more common adenocarcinomas; they are sarcomas, mesenchymal neoplasms that arise from a specific and fascinating cell type: the interstitial cell of Cajal (ICC). ICCs are the "pacemaker" cells of the gastrointestinal tract, forming an intricate network within the muscularis propria, the deep muscle layer of the gut wall.[17] They are responsible for generating the slow-wave electrical activity that coordinates peristalsis, the rhythmic contractions that propel food and waste through the digestive system. Their function is therefore vital to normal gut motility. The link between ICCs and GISTs was definitively established with the discovery that both cell types express a particular cell surface receptor called KIT, also known as CD117. KIT is a receptor tyrosine kinase, a protein that spans the cell membrane and functions as a molecular switch.[18] In normal ICC physiology, the KIT receptor is activated when its specific ligand, stem cell factor (SCF), binds to its extracellular domain. This binding event causes two KIT molecules to pair up (dimerize), which in turn activates their intracellular kinase domains. This activation initiates a cascade of downstream signaling pathways, primarily the RAS-RAF-MEK-ERK (MAPK) pathway and the PI3K-AKT-mTOR pathway. These pathways transmit signals to the cell nucleus, promoting normal cell survival, proliferation, and differentiation, thus maintaining the healthy ICC network. The pathogenesis of the vast majority of GISTs lies in the catastrophic disruption of this tightly regulated process. Approximately 80-85% of GISTs are driven by gain-of-function mutations in the KIT gene itself. These are not inherited mutations but rather somatic mutations that occur spontaneously within a single precursor cell. The most common site for these mutations is in exon 11 of the KIT gene, which codes for the juxtamembrane domain—a region critical for preventing the receptor from activating spontaneously.[18] A mutation here effectively "jams" the switch in the "on" position. The result is a constitutively active KIT receptor that signals relentlessly, independent of its ligand, SCF. This unceasing signaling drives uncontrolled cell proliferation and a profound resistance to apoptosis (programmed cell death), leading to the formation of a tumor. This phenomenon, where a cancer is wholly dependent on a single, aberrant signaling pathway, is known as "oncogene addiction," and it is the central vulnerability of GISTs that has been so successfully exploited by targeted therapies.

A smaller fraction of GISTs (around 5-10%) that lack KIT mutations are instead driven by mutations in a closely related gene, PDGFRA (platelet-derived growth factor receptor alpha). PDGFRA also encodes a receptor tyrosine kinase and, when mutated (most commonly in exon 18), leads to a similar outcome of constitutive activation and tumorigenesis.[18] The remaining 5-10% of GISTs are "wild-type," lacking mutations in either KIT or PDGFRA. This group is more heterogeneous and includes tumors associated with deficiencies in the succinate dehydrogenase (SDH) complex, which are more common in younger patients like the one in this case, or those associated with syndromes like Neurofibromatosis type 1 (NF1). This molecular foundation is not merely academic; it has direct and profound clinical implications. It explains why GISTs are defined by their immunohistochemical profile—the strong and diffuse staining for CD117 (KIT) and, in over 95% of cases, DOG1 ("Discovered on GIST-1"), a calcium-dependent chloride channel protein that is also highly expressed in ICCs. The absence of staining for markers of other mesenchymal cells, like smooth muscle actin (SMA) or desmin (for smooth muscle tumors) and S-100 (for neural tumors), helps to definitively distinguish GIST from its histological mimics. Furthermore, the specific type and location of the mutation (KIT exon 11 vs. exon 9 vs. PDGFRA mutations) can predict the tumor's behavior and its sensitivity to different tyrosine kinase inhibitors, making molecular subtyping a critical component of modern GIST management.[19]



Figure 3. The diagnostic conundrum.

The most dramatic and educational aspect of this case was the stark discordance between the initial biopsy report of a "hyperplastic polyp" and the overwhelming evidence pointing to a massive, life-threatening malignancy. This scenario represents a classic and dangerous pitfall in gastroenterology and serves as a powerful testament to the necessity of clinical reasoning and the integration of multidisciplinary data. A hyperplastic polyp is one of the most common benign epithelial lesions found in the stomach. Histologically, it is characterized by elongated, tortuous gastric pits lined by foveolar epithelium, with an inflamed, edematous lamina propria. These polyps are thought to arise as a regenerative, hyperproliferative response to chronic inflammation or injury, such as that caused by chronic gastritis from *H. pylori* infection (which this patient had) or chemical irritation. They are fundamentally mucosal lesions, confined to the innermost layer of the gastric wall. The diagnostic error in this case arose from a simple, mechanical problem of tissue acquisition. As previously established, GISTs are submucosal tumors arising from the deep muscularis propria. As a GIST grows, it expands and pushes the overlying layers—the submucosa and the mucosa—inward into the gastric lumen. Standard endoscopic biopsy forceps are small pincers designed to skim off tiny fragments of the most superficial layer, the mucosa. When the endoscopist took biopsies from the surface of this patient's giant tumor, the forceps were unable to penetrate through the intact mucosal layer to reach the underlying sarcoma. Instead, they sampled only the stretched, inflamed, and reactive mucosa covering the tumor. The chronic pressure, irritation, and intermittent bleeding from the tumor surface had induced secondary hyperplastic changes in this overlying mucosa, perfectly mimicking the histology of a primary hyperplastic polyp. The pathologist, receiving only these superficial fragments and having no knowledge of the giant submucosal mass beneath, could only issue a report based on the tissue provided, leading to the dangerously misleading benign diagnosis. This situation highlights a cardinal rule in clinical medicine: a diagnostic test result must never be interpreted in a vacuum. It must always be contextualized within the patient's complete clinical picture. In this case, the benign biopsy result was incongruent with every other piece of data: The Clinical Severity: Benign hyperplastic polyps, while they can occasionally bleed, almost never cause the kind of profound, life-threatening anemia (Hb 3.8 g/dL) and dramatic constitutional symptoms (10 kg weight loss) seen in this patient. The Endoscopic Appearance: While the surface may have had polypoid features, the sheer size, the near-complete luminal obstruction, and the presence of ulceration were all hallmarks of a significant neoplasm, not a simple benign polyp. The Radiological Findings: The CT scan was unambiguous. It depicted a massive, 13.5 cm, heterogeneously enhancing mass with features of a sarcoma. This imaging was the single most crucial piece of objective evidence that refuted the benign biopsy. The management of this diagnostic dissonance by the multidisciplinary team was exemplary. They correctly recognized that the biopsy was almost certainly a non-representative sample due to a technical limitation. Instead of being falsely reassured or delaying action, they prioritized the more robust and compelling clinical and radiological data. This is a critical decision-making process for clinicians to understand. When faced with such a contradiction, especially involving a submucosal lesion, the next logical step in an ideal setting would be to pursue a more advanced diagnostic technique. Endoscopic ultrasound (EUS) is the modality of choice in this scenario. EUS would have unequivocally demonstrated the tumor arising from the fourth hypoechoic layer (the muscularis propria), and EUS-guided fine-needle biopsy (FNB) could have procured a deep core tissue sample, providing the correct diagnosis pre-operatively. However, even in the absence of EUS, the team's decision to proceed directly to surgery based on the aggregate data was the correct and life-saving one. This case champions the principle that clinical judgment and the synthesis of high-quality imaging often trump a single, technically limited tissue sample (Figure 3).



Figure 4. The pathophysiology of profound anemia.

The patient's presentation was dominated by the consequences of his profound iron deficiency anemia. Anemia is a common finding in patients with GISTs, reported in up to 50% of symptomatic cases, but the severity seen here (Hb 3.8 g/dL) is at the extreme end of the spectrum and underscores the potential for massive, albeit occult, blood loss. The mechanism is a direct result of the tumor's growth dynamics and its interaction with the overlying gastrointestinal mucosa. As the submucosal GIST expands, it exerts increasing pressure on the overlying mucosal and submucosal layers. This pressure effect compromises the delicate microvasculature that supplies the mucosa, leading to ischemia. The mucosal surface becomes stretched, thin, and attenuated. This combination of ischemia and mechanical stress makes the mucosa extremely friable and prone to breakdown. Spontaneous erosion and ulceration occur on the tumor's surface, exposing the rich network of blood vessels within the tumor and the submucosa. This leads to chronic, low-volume, but relentless bleeding into the gastric lumen. This blood loss is typically "occult," meaning it is not visible to the naked eye as fresh blood (hematemesis) or large-volume melena. Instead, small amounts of blood are continuously lost, digested by stomach acid and enzymes, and passed in the stool, often going completely unnoticed by the patient. A fecal occult blood test, as was positive in this patient, is the standard method for detecting this type of bleeding. The slow, insidious nature of the hemorrhage is what allows the human body to physiologically compensate to a remarkable degree. Had this patient lost the same volume of blood acutely, he would have rapidly progressed to hypovolemic shock and cardiovascular collapse. However, because the loss occurred over weeks to months, his body had time to adapt. The plasma volume expanded to maintain blood pressure, and cardiovascular output increased to ensure oxygen delivery to vital tissues. This compensation, however, comes at the cost of the body's iron stores. Every milliliter of lost blood carries away iron bound within hemoglobin. The body's iron stores, primarily held as ferritin in the liver, spleen, and bone marrow, are progressively mobilized and depleted in an attempt to support the production of new red blood cells (erythropoiesis). Eventually, these stores are completely exhausted. This is the state of absolute iron deficiency, reflected in this patient's critically low serum ferritin level of 1.84 ng/mL (a level <15 ng/mL is considered diagnostic of depleted iron stores). Without sufficient iron, the bone marrow cannot produce functional hemoglobin molecules. Erythropoiesis becomes ineffective, and the red blood cells that are produced are small (microcytic) and pale (hypochromic) because they lack their primary oxygen-carrying component. This cascade of events culminates in the severe iron deficiency anemia that produced the patient's profound fatigue, weakness, pallor, and dyspnea on exertion. His management correctly focused on two immediate goals: first, replacing the lost red cell mass with transfusions to restore oxygen-carrying capacity and prevent end-organ damage; and second, initiating aggressive iron repletion to begin the long process of rebuilding the body's depleted stores, a process that is essential for long-term recovery, especially after a total gastrectomy which itself can impair iron absorption (Figure 4).

The occurrence of a GIST of this magnitude in a 39-year-old is a statistical anomaly. GISTs are predominantly a disease of older adults, with the median age at diagnosis being between 60 and 65.[19] The presentation in a younger individual immediately raises the question of a potential underlying genetic syndrome. While this patient had no overt stigmata of NF1 or Carney triad, the possibility of an SDH-deficient GIST must be considered. SDH-deficient GISTs account for a significant proportion of pediatric, adolescent, and young adult GISTs. They have a distinct biology, often characterized by a more indolent growth pattern (though this patient's tumor was clearly aggressive), a predilection for the stomach, and, crucially, a general resistance to standard imatinib therapy. This underscores the importance of considering molecular testing for SDH subunit mutations in such cases, as it could influence the choice of systemic therapy. The therapeutic management in this case was a model of modern oncologic care, hinging on the principles of complete surgical resection and risk-adapted adjuvant therapy. The primary goal of treatment for any localized GIST is to achieve a complete surgical resection with negative microscopic margins (an R0 resection).[20] This is the single most important factor determining the chance of a cure. The decision to convert from a planned partial gastrectomy to a total gastrectomy intraoperatively was a critical surgical judgment. It was based on the realization that the tumor's massive size and its proximity to the gastroesophageal junction made it impossible to achieve a safe oncologic margin while preserving a functional gastric remnant. A total gastrectomy, while a major life-altering operation, was the necessary procedure to ensure the entire tumor was removed, maximizing the patient's chance of long-term survival.[20]

Following surgery, the focus shifted to risk stratification. Not all GISTs are created equal; their potential for recurrence varies dramatically. The most widely used system for predicting this risk is the modified NIH consensus criteria, which is based on three key factors: tumor size, mitotic rate (the number of dividing cells per unit area, a measure of proliferative activity), and tumor location (gastric GISTs generally have a better prognosis than small intestinal GISTs of similar size and mitotic rate). In this case, the tumor was >10 cm and had a high mitotic rate (8 mitoses/5mm^2), placing it unequivocally in the high-risk category. For patients with high-risk GISTs, surgery alone is insufficient, as the risk of microscopic residual disease leading to recurrence can exceed 50%. This is where the paradigm of adjuvant therapy becomes critical. Based on the landmark ACOSOG Z9001 trial and subsequent studies, the standard of care for patients with high-risk resected GISTs is at least three years of adjuvant therapy with imatinib mesylate (400 mg daily). Imatinib is a small-molecule tyrosine kinase inhibitor that specifically targets the ATP-binding pocket of the aberrant KIT and PDGFRA receptors, switching them off and thereby halting the oncogenic signaling that drives GIST cell growth. Adjuvant imatinib has been proven to dramatically improve recurrence-free survival and has become a cornerstone of GIST management. The plan to initiate this therapy for our patient was therefore essential and evidence-based, offering him the best possible chance of remaining disease-free.

4. Conclusion

This case of a giant gastric GIST in a young man is a powerful and informative clinical vignette that provides profound insights for practicing clinicians. It vividly illustrates that this rare tumor, even in an atypical demographic, can manifest with devastating severity, in this instance as a life-threatening iron deficiency anemia. The central, unforgettable lesson from this patient's journey is the critical importance of clinical synthesis in the face of diagnostic uncertainty. It demonstrates unequivocally that a single, technically limited biopsy result must never be accepted at face value when it contradicts a cohesive and compelling body of clinical, laboratory, and radiological evidence. The diagnostic pitfall of a "benign" report from a superficial biopsy of a deep-seated malignancy is a real and dangerous phenomenon. This case champions the indispensability of a holistic, multidisciplinary approach, urging clinicians to trust their integrated judgment and to pursue a definitive diagnosis through advanced techniques or, as was necessary here, definitive surgical intervention. Ultimately, this report stands as a testament to the principles of careful clinical reasoning, the power of high-quality imaging, and the success of a modern, evidence-based oncologic strategy in achieving a favorable outcome against a formidable disease.

5. References

1. Park JH, Kim SE, Park SJ, Park MI, Moon W, Kim JH, et al. Rapidly growing gastrointestinal stromal tumor on the esophagus. Korean J Helicobacter Up Gastrointest Res. 2025; 25(1): 64–9.
2. Bai G-Y, Shan K-S, Li C-S, Wang X-H, Feng M-Y, Gao Y. Gastric gastrointestinal stromal tumor in a patient with neurofibromatosis type I presenting with anemia: a case report. World J Gastrointest Oncol. 2025; 17(3): 99304.

3. Zhao S-Q, Wang S-Y, Ge N, Guo J-T, Liu X, Wang G-X, et al. Endoscopic full-thickness resection vs surgical resection for gastric stromal tumors: Efficacy and safety using propensity score matching. World J Gastrointest Surg. 2025; 17(3): 101002.
4. Kim JH, Wang J, Magahis P, Adejumo A, Hanscom M, Carr-Locke D, et al. Endoscopic full-thickness resection of a duodenal gastrointestinal stromal tumor. VideoGIE. 2025.
5. Sun Y-F, Cao X-K, Wei Q, Gao Y-H. Potential biomarkers for the prognosis of gastrointestinal stromal tumors. World J Gastrointest Oncol. 2025; 17(4): 102831.
6. Zhu S, Dai N, Guo C, Ullah S, Cao X. Imatinib neoadjuvant endoscopic resection of a giant gastrointestinal stromal tumor (GIST): a pioneering exploration in GIST treatment history. Gastrointest Endosc. 2025; 101(5): S98.
7. Zhu S, Dai N, Ullah S, Guo C, Cao X. Endoscopic versus laparoscopic resection for gastrointestinal stromal tumors of esophagogastric junction (EGJ-GIST): a propensity score-matched study. Gastrointest Endosc. 2025; 101(5): S226.
8. Ishfaq H, Soomro MY, Masood B, Ahmed R, Rashid YA. Concurrent coprimary KIT Exon 17 and BRAF mutations in a small intestinal GI stromal tumor-a case report. J Gastrointest Cancer. 2025; 56(1): 116.
9. Bencini L, Adinolfi E. Minimally invasive approaches to small gastric stromal tumors: The less with the more. World J Gastrointest Surg. 2025; 17(5): 101823.
10. Ren X, Wang G, Chen J, Liu L. A population-based analysis of gender differences in survival outcomes for gastric gastrointestinal stromal tumors. J Gastrointest Surg. 2025; 29(6): 102055.
11. Li J, Ye Y, Wang J, Zhang B, Qin S, Shi Y, et al. Chinese consensus guidelines for diagnosis and management of gastrointestinal stromal tumor. Chin J Cancer Res. 2017; 29(4): 281–93.
12. Liu X, Qiu H, Wu Z, Zhang P, Feng X, Chen T, et al. A novel Pathological Prognostic Score (PPS) to identify "very high-risk" patients: a multicenter retrospective analysis of 506 patients with high risk gastrointestinal stromal tumor (GIST). J Gastrointest Surg. 2018; 22(12): 2150–7.
13. Li J, Wang M, Zhang B, Wu X, Lin T-L, Liu X-F, et al. Chinese consensus on management of tyrosine kinase inhibitor-associated side effects in gastrointestinal stromal tumors. World J Gastroenterol. 2018; 24(46): 5189–202.
14. Liu X, Qiu H, Zhang P, Feng X, Chen T, Li Y, et al. Prognostic factors of primary gastrointestinal stromal tumors: a cohort study based on high-volume centers. Chin J Cancer Res. 2018; 30(1): 61–71.
15. Liu X, Qiu H, Zhang P, Feng X, Chen T, Li Y, et al. Ki-67 labeling index may be a promising indicator to identify "very high-risk" gastrointestinal stromal tumor: a multicenter retrospective study of 1022 patients. Hum Pathol. 2018; 74: 17–24.
16. Begum FA, Rahman MA, Rabbi H, Mostofa G, Chowdhury Q. Primary jejunal gastrointestinal stromal tumor: Diagnosis delay of 3 years but successful management in early stage (II) by surgery and adjuvant therapy. Gastrointest Tumors. 2019; 6(1–2): 36–42.
17. Geramizadeh B, Shojazadeh A. Gastrointestinal stromal tumor of the ampulla of Vater: a narrative review. Gastrointest Tumors. 2021; 8(3): 101–6.
18. Yang Z, Feng X, Zhang P, Chen T, Qiu H, Zhou Z, et al. Clinicopathological features and prognosis of 276 cases of primary small (≤ 2 cm) gastric gastrointestinal stromal tumors: a multicenter data review. Surg Endosc. 2019;

33(9): 2982–90.

19. Pizzini P, Coppola S, Ascari F, Manara M, De Pascale S. A narrative review of minimally invasive techniques for treatment of gastric gastrointestinal stromal tumors. Gastrointest Stromal Tumor. 2022; 5: 7.
20. Bentley BH, Ellington AL, Guo AA, Lu H, Lippert WC. Jejunal leiomyosarcoma in a young adult: Distinguishing from gastrointestinal stromal tumor through radiographic, histologic, and epidemiologic analysis - a case report. Gastrointest Tumors. 2023; 10(1): 38–43.